Bio-Bridge Science Issues Corporate Update.

OAK BROOK, Ill. -- Bio-Bridge Science, Inc. (OTCBB:BGES), a biotechnology company engaged in the commercial development of vaccines for the prevention and treatment of human infectious diseases issues a corporate update today.

The Company's strategy is to develop its own vaccines, to establish a vaccine and drug distribution network, and to acquire promising vaccine-producing and vaccine-related companies in China to diversify product offerings.

Complementary Acquisition

The Company is in discussions with several potential acquisition targets in China. These targets are primarily vaccine companies with increasing vaccine sales and stable sales channels. Other targets include vaccine development and production-related companies. Our short-term goal is to acquire one of these vaccine companies, which will increase our product offerings and revenues, and establish our first sales channel in China. Our goal is to acquire at least 51% of a target company at a reasonable price. We will provide further information when an acquisition agreement has been signed.

In-House Vaccine Product Development

HIV vaccine: The pre-clinical studies of our HIV Vaccine on laboratory animals were completed by the Beijing Institute of Radiation Medicine and showed encouraging results. After the vaccine samples are produced in our GMP facility in Beijing, we will submit application for clinical trials with the SFDA.

Second generation of a HPV vaccine (a polyvalent vaccine): We entered into a cooperative agreement with the Institute of Basic Medical Sciences at the Chinese Academy of Medical Sciences, a leading medical research institute in China, to research and develop a human papillomavirus polyvalent vaccine using prokaryotic expression system (HPV vaccine). This vaccine is designed to prevent from infection by human papillomavirus types 6, 11, 16, 18, 31, 45, and 58 and would, if successful, prevent more types of HPV infection than the current vaccines in the market and the cost of the production will be significantly lower. Currently the pre-clinical study of the HPV vaccine is under way. We expect that the pre-clinical study can be completed in the second half of 2008.

Facility Completion Update

The electricity project for our GMP facility in Beijing is in process and the Company expects the project to be completed in the second half of 2007. We expect at that time the facility will be fully operational.

Dr. Liang Qiao, Chairman and CEO of Bio-Bridge Science said, "We believe that a completion of our planned acquisition will enable us to increase our revenue and build a vaccine and drug distribution network in China. Also, our association with leading medical research institutes in China will solidify our research capability as we try to introduce more potential vaccine products in addition to our current vaccines in development."

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. Please refer to the Company's SEC filings for additional information.